SOURCE: Cutting Edge Information

Cutting Edge Information Home

August 25, 2017 09:21 ET

More Than Half of Surveyed Life Science Teams Prefer to Centralize Preclinical Structures Geographically

RESEARCH TRIANGLE PARK, NC--(Marketwired - August 25, 2017) - A new study of early-stage product development teams found that the highest percentage of survey respondents – 62% – indicate that their preclinical function is geographically centralized.

Data collected and analyzed by business intelligence firm, Cutting Edge Information, revealed that an additional 24% of surveyed pharmaceutical companies opt to centralize their preclinical function by therapeutic area. Centralized structures may prove to be helpful – particularly as preclinical teams align their operations under country-specific guidelines.

The study, Early-Stage Product Development: Strengthen Research and Development Outcomes with Robust Structures and Resources, compared pharmaceutical companies at global and country levels to discover how they arrange their preclinical groups differently. Within the US, centralized preclinical functions are a predominant theme across surveyed life science teams at the global level.

Outside of the US, the study found that country-level teams typically decentralize their preclinical groups, either by therapeutic area, geography, or a mixture of both.

"Centralized preclinical structures are not unique to any specific type of life science organization," said Sarah Ray, senior research analyst at Cutting Edge Information. "This all-encompassing trend emphasizes that applicable FDA guidance covers operations of all pharmaceutical group types."

Cutting Edge Information's study, Early-Stage Product Development: Strengthen Research and Development Outcomes with Robust Structures and Resources, available at https://cuttingedgeinfo.com/product/early-stage-product-development/, provides an overview of preclinical structures, resources and activity types. Report highlights include:

  • Data on preclinical teams' structural organizations and staffing levels
  • Comparisons of preclinical funding levels against annual R&D budgets
  • Projected costs associated with preclinical study types
  • Best practice recommendations and metrics detailing preclinical teams' outsourcing practices

For more information about R&D structures, resources and workloads, please visit https://cuttingedgeinfo.com/product-category/clinical-development/.

Image Available: http://www.marketwire.com/library/MwGo/2017/8/9/11G143972/Images/August_25_2017_-_PH229_-_More_Than_Half_of_Surveye-d26597f1e3069c59b54202080fe61044.jpg

Contact Information